Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability and efficacy of every-2-week dosing of
QLF31907 injection in patients with advanced melanoma and urothelial carcinoma.